Prophylactic and therapeutic monoclonal antibodies

• US 6,620,412 B2
• Filed: 09/16/2002
• Issued: 09/16/2003
• Est. Priority Date: 02/11/2000
• Status: Expired due to Term

• Current Assignee: The United States Of America As Represented By The Secretary Of The Army
• Original Assignee: The United States Of America As Represented By The Secretary Of The Army
• Inventors: Hooper, Jay W., Schmaljohn, Connie S., Schmaljohn, Alan L.
• Primary Examiner(s): SCHEINER, LAURIE A
• Application Number:
  US10/202,532
• Publication Number:
  US 20030022226A1
• Time in Patent Office: 365 Days
• Field of Search: 424/147.1, 424/232.1, 424/184.1, 530/388.3
• US Class Current: 424/147.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: C07K 16/081 from DNA viruses

Abstract

In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.

Claims

1. A composition comprising a monoclonal antibody directed against a homolog of vaccinia L1R, a monoclonal antibody directed against a homolog of vaccinia A33R, and at least one monoclonal antibody directed against an antigen selected from the group consisting of vaccinia H3L, D8L, B5R, A27L and A17L.

2. The composition of claim 1, which composition further comprises at least one monoclonal antibody directed against an antigen selected from the group consisting of analogs of vaccinia H3L, D8L, B5R, A27L and A17L.

3. The composition of claim 1, wherein the monoclonal antibodies are reactive against at least one poxvirus chosen from the group consisting of orthopoxvirus, parapoxvirus, avipoxvirus, capripoxvirus leporipoxvirus, suipoxvirus, molluscipoxvirus, and yatapoxvirus.

4. The composition of claim 1 wherein said composition inhibits vaccinia virus infection in a subject in vivo.

5. The composition of claim 4 wherein said subject is avian or mammalian.

6. The composition of claim 1 wherein said composition ameliorates symptoms of vaccinia virus infection when said composition is administered to a subject after infection with vaccinia virus.

7. The composition of claim 6 wherein said subject is avian or mammalian.

8. A therapeutic composition for ameliorating symptoms of vaccinia virus infection comprising the composition of claim 1, and a pharmaceutically acceptable excipient.

9. A passive vaccine against vaccinia virus infection comprising the composition of claim 1.

11. A method of treating vaccinia virus infection comprising administering to patient in need of said treatment an effective amount of a composition according to claim 1.

12. The composition according to claim 2, wherein the composition comprises a monoclonal antibody directed against a homolog of vaccinia A33R, a monoclonal antibody directed against a homolog of vaccinia L1R, a monoclonal antibody directed against a homolog of vaccinia B5R, and a monoclonal antibody directed against a homolog of vaccinia A27L.

13. The composition of claim 1, wherein the homolog of vaccinia L1R is at least 90% homologous to the vaccinia L1R, and the homolog of vaccinia A33R is at least 90% homologous to the vaccinia A33R.

10. An anti-vaccinia composition, comprising a monoclonal antibody directed against a homolog of vaccinia A33R, a monoclonal antibody directed against a homolog of vaccinia L1R, and at least one monoclonal antibody directed against an antigen selected from the group consisting of homologs of vaccinia H3L, D8L, B5R, A27L and A17L, in an amount effective for inhibiting vaccinia virus infection, and a pharmaceutically acceptable carrier.

14. A composition comprising a monoclonal antibody directed against vaccinia B5R, and a monoclonal antibody directed against vaccinia A27L.